Description
Interferon (IFN) therapy works in part by inhibiting myeloid-derived suppressor cells (MDSC). In the clinic, routine flow cytometry can assess MDSC activity by measuring reactive oxygen species (ROS), intracellular pSTAT3, and serum arginase 1. What the researchers observed is that cancer patients that respond well to a full course of IFN treatment also exhibited a measurable drop in these MDSC markers following a single test dose of IFN in the clinic. On the other hand, patients that didn’t respond to IFN therapy also didn’t show any MDSC marker changes following the test dose. This simple test — the first of its kind — enables clinicians to screen patients for IFN therapy based on their likely responsiveness to treatment. Advantages This is the only test that predicts which patients will respond to IFN therapy The test is easily performed Enables non-responders to save time and money, while also avoiding unnecessary toxic exposure.
IP Status
https://patents.google.com/patent/US10627403B2
